急性胰腺炎患者血清TNF-α、IL-6和IL-8含量测定

研究血清TNF α、IL 6和IL 8在急性胰腺炎 (AP )发生发展中的作用和临床意义。采用双抗体夹心ELISA法测定 41例AP患者及正常对照组 40例血清TNF α、IL 6、IL 8和C 反应蛋白 (CRP )水平。结果显示 ,重症急性胰腺炎 (SAP )和轻症急性胰腺炎 (MAP )血清TNF α、IL 6、IL 8和CRP水平较正常对照组明显增高 (P <0 0 5 ) ,SAP组又较MAP组增高 (P <0 0 5 )。2 7例MAP患者血清TNF α、IL 6、IL 8和CRP水平在治疗后 3d已有下降 ,7d降至正常水平。 14例SAP患者血清TNF α、IL 6、IL 8和CRP水平在治疗后 7d明显降低 ,2 1d仍未降至正常水平。血清中TNF α、IL 6和IL 8可能与AP的严重程度相关 ,在临床上联合检测血清TNF α、IL 6、IL 8和CRP可用于AP的病情严重程度判定和观察治疗后疗效及病情恢复的情况     

血清SAA、 CRP、 ACE 2对重症胰腺炎的临床诊断价值分析

目的 分析血清淀粉样蛋白A(SAA)、C反应蛋白(CRP)和血管紧张素转化酶2(ACE 2)水平在急性胰腺炎,尤其是重症胰腺炎临床诊断中的应用价值.方法 选取2017年10月至2019年10月本院收治的100例急性胰腺炎患者,其中61例轻症急性胰腺炎为轻症组,39例重症急性胰腺炎为重症组;同时选取同期来院体检的100例健康志愿者为对照组.采集治疗前空腹静脉血,分离血清,采用ELISA实验检测血清SAA、CRP和ACE 2水平.结果 重症组SAA、CRP水平明显高于轻症组,且均高于对照组,差异具有统计学意义(P＜0.05);重症组ACE 2水平明显低于轻症组,且均低于对照组,差异具有统计学意义(P＜0.05).39例重症急性胰腺炎患者血清SAA水平与CRP呈正相关(r=0672,P＜0.01);SAA与ACE 2呈负相关(r=-0.619,P＜0.05);CRP与ACE 2呈负相关(r=-0.525,P＜0.05).三者联合诊断急性胰腺炎和预测重症急性胰腺炎的ROC曲线下面积分别为0.822、0.807.结论 重症急性胰腺炎患者血清SAA、CRP和ACE与病情严重程度具有一定关系,三者联合检测诊断急性胰腺炎和预测重症急性胰腺炎具有较高的临床价值.     

急性胰腺炎患者血浆leptin．和血清hs-CRP、IL-6和IL-8检测的临床意义

目的：探讨了急性胰腺炎患者血浆leptin和血清hs-CRP、IL-6和IL-8水平的变化及临床意义。方法：应用放射免疫分析和免疫比浊法对30例急性胰腺炎患者进行了血浆leptin和血清hs．CRP、IL-6和IL．8检测,并与35名正常健康人作比较。结果：急性胰腺炎患者血浆leptin和血清hs-CRP、IL-6和IL-8水平均非常显著地高于正常人组（P〈0．01）且急性胰腺炎患者血浆leptin和血清hs-CRP、IL-6和IL．8水平呈正相关（r=0．6132、0．5786、0．6218,P〈0．01）。结论：检测急性胰腺炎患者血浆teptin与血清hs．CRP、IL-6和IL-8水平的变化对观察病情发展及预后判断均有重要的临床价值。     

肺癌患者化疗前后血清IL-2,SIL-2R检测的临床意义

目的 :分析了 36例肺癌患者化疗前后血清中IL - 2和SIL - 2R水平的变化。方法 :采用放射免疫分析法测定患者血清中IL - 2和使用ELISA法测定SIL - 2R含量 ,并与 35名正常健康人作比较。结果 :化疗前IL- 2活性明显低于正常人 ,SIL - 2R水平明显高于正常人 (P <0 .0 1 ) ,化疗后 6个月复发者IL - 2 /SIL - 2R水平持续异常 ,未复发者IL - 2 /SIL - 2R水平恢复正常。结论 :观察肺癌患者免疫功能的变化与患者的病情和预后密切相关。     

肺癌患者化疗前后SIL-2R和TNF检测的临床意义

目的 :探讨了 4 0例肺癌患者化疗前后血清中SIL - 2R和TNF含量的变化。方法 :应用放免法和酶免法检测 4 0例肺癌患者血清中SIL - 2R和TNF含量并与 35名正常人作比较。结果 :肺癌患者在化疗前血清中SIL - 2R和TNF含量显著地高于正常人组 (p <0 0 1 ) ,化疗后明显下降 (p <0 0 5 )。 结论 :血清中SIL- 2R和TNF水平可作为肺癌患者免疫功能监测指标之一 ,并可作为疗效判断参考     

卵巢癌患者血清CA125、SIL-2R联检的临床意义

目的 :探讨了血清CA1 2 5、SIL - 2R在卵巢癌诊断和疗效观察中的临床价值。方法 :应用微粒子酶免疫分析法 (MEIA)和酶联吸附法对 36例卵巢癌患者和 5 1例妇科良性肿瘤患者进行了血清CA1 2 5和SIL - 2R水平检测 ,并以 35名正常健康人作对照。结果 :卵巢癌患者血清CA1 2 5、SIL - 2R水平非常显著地高于正常人组(p <0 0 1 ) ,经治疗后三个月血清CA1 2 5、SIL - 2R水平显著下降 ,与正常人组比较 ,无显著性差异 (p >0 0 5 ) ,妇科良性肿瘤组血清与正常人组比较无显著性差异 (p>0 0 5 )。结论 :血清CA1 2 5、SIL - 2R水平检测对卵巢癌的检测具有较高的诊断价值 ,且有助于病情的观察和疗效的监测     

急性胰腺炎患者PCT、ALB、AMY及CRP水平检测的临床价值

目的探讨急性胰腺炎患者降钙素原(PCT)、血清白蛋白(ALB)、淀粉酶(AMY)及C反应蛋白(CRP)水平检测的临床价值。方法选取2016年11月至2017年12月在我院接受治疗的急性胰腺炎(AP)患者109例作为AP组,包括50例轻症急性胰腺炎(MAP)患者和59例重症急性胰腺炎(SAP)患者,同时选取在我院体检的50例健康人作为对照组。分别采用电化学发光法、溴甲酚绿法、干片法和免疫比浊法对血清PCT、ALB、AMY及CRP水平进行检测。分析4种指标单独及联合检测对急性胰腺炎诊断的意义。结果 AP组患者血清PCT、AMY和CRP水平明显高于对照组(P<0.05),且SAP组患者血清PCT、AMY和CRP水平与MAP组相比有明显升高(P<0.05);AP组患者血清ALB水平与对照组相比显著降低(P <0.05),与MAP组相比,SAP组患者血清ALB水平降低程度更为显著(P <0. 05)。AP组PCT、ALB、AMY及CRP单独及联合检测的阳性率均高于对照组(P <0. 05),且AP组联合检测的阳性率均显著高于单项指标检测(P <0. 05)。PCT、ALB、AMY及CRP联合检测的灵敏度为94.50%,准确度为89.31%,明显高于单项检测指标的结果 (P <0.05)。结论 PCT、ALB、AMY及CRP联合检测可显著提高急性胰腺炎诊断的灵敏度和准确度,具有较好的临床应用价值。     

大隐静脉曲张光凝治疗后血清IL-2和sIL-2R的测定

目的 :测定大隐静脉曲张血管内光凝治疗前后血清中白细胞介素 - 2 (sIL - 2R)及其可溶性受体(sIL - 2R)的变化。方法 :5 0例大隐静脉曲张患者根据症状分为轻、重两组 ,取静脉血液 ,分别采用放射免疫分析和双抗体夹心间接ELISA法检测血清中IL - 2和sIL - 2R水平。另外取 30例正常成人血清作为对照。结果 :大隐静脉曲张患者轻症组患者血清中IL - 2和sIL - 2R较正常水平没有明显改变 ;随着病情的加重 ,IL - 2水平明显降低 ,sIL - 2R水平明显升高。治疗后两组IL - 2先下降 ,后逐渐升高 ;sIL - 2R水平先升高 ,后下降。轻症组IL - 2和sIL - 2R稳定水平接近术前 ;而重症组IL - 2稳定后水平高于治疗前 ,sIL - 2R稳定水平低于治疗前水平。结论 :IL - 2和sIL - 2R水平测定可了解静脉曲张患者免疫功能状态 ,判定治疗后病情恢复情况。     

麻疹患者血清SIL-2R和T淋巴细胞亚群的相关性探讨

目的 :探讨了血清可溶性白细胞介素 - 2受体 (SIL - 2R)和T淋巴细胞亚群在麻疹感染中的作用。方法 :应用双抗体夹心ELISA法和单克隆抗体法对 37例麻疹患者进行了血清SIL - 2R和T淋巴细胞亚群测定 ,并以 35例正常人作对照。结果 :麻疹患者在出疹期血清SIL - 2R水平显著地高于正常人组 (P <0 0 1) ,至恢复期虽然血清SIL - 2R水平有所下降 ,但与正常人组比较仍有显著性差异 (P <0 0 1)。SIL - 2R水平与T淋巴细胞亚群中CD8细胞比值密切相关。结论 :检测麻疹患者血清SIL - 2R和T淋巴细胞亚群水平可作为患者病情变化、预后判断的重要检测指标。     

过敏性紫癜患儿血清sIL-2R、IL-6、IL-8 及凝血功能的变化

目的　探讨过敏性紫癜 (HSP)患儿血清可溶性白介素 2受体 (sIL - 2R)、白介素 6 (IL - 6 )、白介素 8(IL - 8)及部分凝血活酶时间 (APTT)、凝血酶时间 (TT)、D -D二聚体在发病过程中的变化。方法　应用化学发光法检测sIL - 2R、IL -6、IL - 8水平 ,用SymexCA - 15 0 0全自动血凝分析仪测定APTT、TT及D -D二聚体。结果　HSP患儿急性期血清sIL - 2R、IL- 6、IL - 8水平明显高于正常 (P <0 0 5 ) ,3个月后恢复至正常对照组水平 (P >0 0 5 )。早期血液呈高凝状态 ,APTT、TT缩短 ,伴继发性纤溶 ,D -D二聚体增高 ,且混合型增高更显著。结论　动态检测HSP患儿血清sIL - 2R、IL - 6、IL - 8及APTT、TT、D -D二聚体的变化 ,为临床判断病情 ,估计预后及抗凝治疗提供理论依据。     

血清ICAM-1、SIL-2R、IL-2水平对重症急性胰腺炎患者病情及预后评估的临床价值

目的探讨血清细胞间黏附分子-1(ICAM-1)、可溶性白介素2受体(SIL-2R)、白细胞介素-2(IL-2)水平对重症急性胰腺炎(AP)患者病情及预后评估的价值。方法回顾性收集2016年2月至2019年2月收治的重症AP 51例作为重症组,收集同期收治的轻症AP 40例作为轻症组,选取同期来医院体检且留存完整血样标本的30例作为对照组,酶联免疫吸附法(ELISA)测定血ICAM-1、SIL-2R、IL-2水平,并进行病情Ranson评分,分析三者与AP病情进展及重症AP预后的关系。结果轻症组、重症组入院时血清ICAM-1、SIL-2R水平高于对照组,IL-2水平低于对照组(P<0.05),重症组血清ICAM-1、SIL-2R水平高于轻症组,IL-2水平低于轻症组P<0.05);重症组入院时Ranson评分高于轻症组(P<0.05);死亡组血清ICAM-1、SIL-2R及Ranson评分均高于生存组,IL-2水平低于生存组(P<0.05);ICAM-1与SIL-2R、Ranson评分均呈正相关(r=0.784、0.560,P均<0.05),与IL-2呈负相关(r=-0.486,P<0.05),SIL-2R与Ranson评分呈正相关(r=0.688,P<0.05),与IL-2呈负相关(r=-0.567,P<0.05),IL-2与Ranson评分呈负相关(r=-0.523,P<0.05);ICAM-1>183.83ng/mL时,预测重症AP灵敏度、特异性分别为86.27%、92.50%;SIL-2R>45.75 pg/mL时预测重症AP灵敏度、特异性分别为88.24%、90.00%;IL-2<3.41 pg/mL时预测重症灵敏度、特异性分别为84.31%、90.00%。结论AP伴明显ICAM-1、SIL-2R表达上调,IL-2表达降低,三者均与AP病情进展有关,可作为预测重症AP发病及评估AP预后的依据。     

食管癌患者手术前后血清IL—2与SIL—2R水平的检测

采用ＭＴＴ比色法与双抗体夹心法对３８例食管癌患者进行了手术前后ＩＬ－２与ＳＩＬ－２Ｒ水平检测,并以正常人作对照。结果表明：食用癌患者手术前血清ＩＬ－２活性明显低于正常人,血清ＳＩＬ－２Ｒ水平明显地高于正常人;术后６个月复发者ＩＬ－２与ＳＩＬ－２Ｒ持续异常,未复发者ＩＬ－２与ＳＩＬ－２Ｒ水平恢复正常。观察了患者免疫功能的变化与肿瘤的发生及预后密切相关。     

Serum amyloid A in autoimmune thrombosis

The objectives of this study were (1) to determine how levels of serum amyloid A (SAA), high sensitivity C-reactive protein (CRP) and interleukin-6 (IL-6) correlate to autoimmune diseases in patients with or without thrombosis, and (2) to discuss the parameters that influence the relative SAA values. SAA, CRP and IL-6 concentrations were determined by enzyme linked immunosorbent assay (ELISA). 84 patients with secondary antiphospholipid syndrome (SAPS), primary antiphospholipid syndrome (PAPS), systemic lupus erythematosus with antiphospholipid antibodies (SLE+aPL), SLE, venous thrombosis (VT), arterial thrombosis (AT) were compared to healthy donors (n=60). The percentages of patients above cut-off were highest in the SAPS, SLE and SLE+aPL groups. Significant differences were observed between healthy donors and inflammatory groups of patients (SAPS and SLE+aPL) in all three measured parameters. SAA and CRP were shown to be correlated to a greater extent in SAPS patients than SLE+aPL patients. In summary, this cross-sectional, retrospective, small study and accompanying clinical considerations limit the ability to make definite conclusions. SAA would not serve as a useful marker for venous, arterial thrombosis or PAPS (pro-coagulant events). It could however, be a good predictor of progression from a non-inflammatory thrombotic condition to an inflammatory one.     

Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone.

The hepatic production of the acute phase proteins in response to inflammatory cytokines, and the interaction of corticosteroids within this response, has been the subject of considerable recent research. In this study we have examined the effects of the corticosteroid prednisolone on the production of IL-1 alpha and IL-1 beta by lipopolysaccharide (LPS)-stimulated monocytes, and the ability of the monocyte conditioned media (MOCM) obtained under these conditions to induce human hepatoma HepG2 cells to produce serum amyloid A (SAA) and C-reactive protein (CRP). We also examined the production of SAA and CRP by HepG2 cells exposed to different combinations and concentrations of recombinant human (rh) IL-1 alpha, rhIL-1 beta, rhIL-6, recombinant human tumour necrosis factor-alpha (rhTNF-alpha) and prednisolone. The findings indicate: (i) prednisolone substantially inhibits the production of both IL-1 alpha and IL-1 beta by LPS-stimulated monocytes. The MOCM from prednisolone-treated monocytes induced less SAA and CRP production by HepG2 cells; (ii) IL-1 alpha and IL-1 beta both induced CRP and SAA synthesis by HepG2 cells, but only in the presence of IL-6. IL-1 beta was the more potent inducer for SAA production, but for CRP production IL-1 alpha and IL-1 beta were equivalent; (iii) prednisolone enhances the production of SAA by HepG2 cells, but does not enhance the production of CRP; (iv) TNF-alpha in the presence or absence of IL-6 and/or prednisolone did not induce the production of SAA or CRP by HepG2 cells. These findings offer a tenable solution to a disparate production of SAA compared with CRP in corticosteroid-treated cystic fibrosis (CF) patients.     

卵巢癌患者化疗前后血清CA125、IL-2和SIL-2R检测的临床应用

目的:探讨了卵巢癌患者化疗前后血清CA125、IL-2和SIL-2R水平的变化及临床意义。方法:采用放射免疫分析和酶联法对36例卵巢癌患者进行了化疗前后血清CA125、IL-2和SIL-2R检测,并与35名正常健康妇女作比较。结果:卵巢癌患者在化疗前血清CA125、SIL-2R水平非常显著地高于正常妇女组(P<0.01),而IL-2水平又非常显著地低于正常妇女组(P<0.01),化疗后6个月复发者血清IL-2、CA125、SIL-2R水平持续异常,未复发者血清IL-2、CA125、SIL-2R水平恢复正常。结论:观察卵巢癌患者免疫功能的变化与患者的病情及预后密切相关。     

急性胰腺炎患者垂体-甲状腺轴的变化及意义

目的 :探讨急性胰腺炎患者垂体 -甲状腺轴的功能变化及意义。方法 :用放射免疫分析 73例急性胰腺炎患者和 33例正常人血清T3 、FT3 、T4、FT4、rT3 、TSH水平 ,其中轻型急性胰腺炎 (mAP) 5 7例 ,重症急性胰腺炎 (sAP) 16例 ,并检测了其中 39例患者 (mAP2 8例 ,sAP11例 )恢复期血清上述激素水平。结果 :急性胰腺炎(mAP组和sAP组 )急性期T3 、FT3 、TSH显著低于正常 (p均 <0 0 5 ) ,rT3 升高 (p <0 0 1) ,恢复期T3 、FT3 虽有回升(与急性期比较p <0 0 1,0 0 5 ) ,但仍未恢复到正常水平 (与正常对照组比较p<0 0 1) ,rT3 恢复正常。mAP组急性期T4、FT4无异常改变 ,恢复期TSH接近正常 (p >0 0 5 ) ,sAP组急性期T4、FT4降低 ,与正常对照比较 (p <0 0 1) ,恢复期T4、FT4有所升高 (与急性期比较p<0 0 1) ,但均未达到正常水平 (p均 <0 0 1) ,同时发现mAP组T3 、FT3 、T4、FT4均高于sAP组 ,而rT3 、TSH两组无差异 (p >0 0 5 )。结论 :血清T3 、FT3 、T4、FT4水平可作为急性胰腺炎病情严重程度评估的一个指标。     

类风湿关节炎患者血清和关节液细胞因子水平的变化及临床意义

目的探讨幼年类风湿关节炎(JRA)及类风湿关节炎(RA)患者IL-6、IL-8、sIL-2R和TNF-α等细胞因子(CK)水平的变化,及其与风湿活动的传统指标血沉(ESR)和C-反应蛋白(CRP)的相关性。方法采用夹心ELISA法,对30例JRA和34例RA患者的血清中,4例JRA、7例RA、6例骨性关节炎(OA)和9例半月板损伤(MT)患者的关节液中IL-6、IL-8、sIL-2R和TNF-α的水平进行检测。结果①30例JRA、34例RA患者血清IL-6和sIL-2R的水平与对照组相差非常显著(P〈0.01);30例JRA患者血清IL-8水平与对照组比较相差显著(P〈0.05)。②JRA全身型、少关节型患者血清IL-8、sIL-2R的水平和JRA多关节型患者血清IL-6的水平与对照组相差非常显著(P〈0.01)。③4例JRA及7例RA患者关节液sIL-2R的水平和RA患者关节液的IL-6水平与对照组相差显著(P〈0.05)。④JRA患者血清IL-6和sIL-2R的水平与ESR和CRP的变化呈明显的相关关系(r值分别为0.532和0.621)。结论①IL-6、sIL-2R的水平与JRA、RA病的活动性有关,是类风湿活动性的主要指标。②sIL-2R不仅参与JRA和RA的全身病理损伤,而且是引起关节局部损伤的主要CK,IL-6也参与JRA关节局部的病理损伤,在RA关节局部损伤似乎更为重要。③IL-8主要参与JRA的全身病理损伤,对关节局部病理损伤似乎并不重要。     

Circulating interleukin 10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: Preliminary report

In order to evaluate the relationship between serum concentrations of interleukin-10 (IL-10), IL-6, and acute phase proteins in rheumatoid arthritis (RA) patients treated with methotrexate (MTX) or intramuscular gold (IMG) we determined IL-10, IL-6, C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP) and alpha-1-antichymotrypsin (ACT) in the sera of 35 RA patients. IL-10 and IL-6 levels were evaluated using an enzyme-linked immunoassay (ELISA). AGP and ACT level were measured using rocket immunoelectrophoresis. IL-10 serum level was not increased in RA patients as compared to controls (58.7 ± 18.1 pg/ml vs. 57.2 ± 11.9 pg/ml). IL-6 level was significantly elevated (91.6 ± 46.9 pg/ml vs. 45 ± 19 pg/ml, p < 0.05). CRP was significantly increased as compared to healthy controls (35 ± 19 mg/l vs. 3 ± 2 mg/l, p < 0.05). Patients treated with MTX or IMG presented an increased level of IL-10 and decreased amounts of IL-6, as compared to those treated with NSAID only. However, only changes between patients treated with IMG and NSAID were found to be statistically significant. A good negative correlation between IL-10 and IL-6 serum level was found (r = –0.75, p < 0.05). A positive significant correlation between IL-6 serum level and CRP (r = 0.62, p < 0.05), AGP (r = 0.78, p < 0.05) and ACT (r = 0.45, p < 0.05) was established. On the other hand, a negative correlation between IL-10 and serum level of CRP (r = –0.76, p < 0.05), AGP (r = –0.64, p < 0.05) and ACT (r = –0.38, p < 0.05) was also observed. Moreover, these relationships were maintained when patients treated with MTX, IMG, or NSAID were analyzed independently. According to the data thus far obtained, it seems that IL-10 decreases IL-6 production, and thereby indirectly affects the acute phase response, decreasing CRP, AGP, and ACT concentration in RA patients.Abbreviations ACT -1-antichymotrypsin - AGP ₁-acid glycoprotein - APP acute phase protein - CRP C-reactive protein - CSF colony stimulating factor - IFN interferon - IL interleukin - IMG intramuscular gold - MTX methotrexate - NSAID non-steroidal anti-inflammatory drug - RA rheumatoid arthritis